Group 1 - Shanghai Zhiyuan Hengyue plans to acquire 37% of the shares of Shangwei New Materials at a price of 7.78 yuan per share, requiring a maximum total funding of 1.16 billion yuan [1] - The acquisition period is set for 30 calendar days, from September 29, 2025, to October 28, 2025 [1] - Zhiyuan Hengyue and Zhiyuan Xinchuan intend to acquire at least 63.62% and up to 66.99% of Shangwei New Materials' shares [2] Group 2 - Heng Rui Pharmaceutical has signed a licensing agreement for the innovative drug SHRA1811, receiving an upfront payment of 18 million dollars and is eligible for up to 1.093 billion dollars in milestone payments [3] - The agreement aims to expand the overseas market for SHRA1811 and enhance the company's innovative brand and overseas performance [3] Group 3 - Tian Shili's subsidiary has received approval for clinical trials of TSL2109 capsules, a dual-target small molecule inhibitor for advanced solid tumors, with no similar drugs currently in clinical trials [4] - The cumulative R&D investment in TSL2109 capsules by Jiangsu Diyi has reached 24.6251 million yuan [4] Group 4 - Wanhui High-tech expects a net profit of 340 million to 420 million yuan for the first three quarters, representing a year-on-year growth of 69.81% to 109.77% [5]

汇宇制药(688553.SH)公告，公司股东王晓鹏女士拟通过集中竞价和大宗交易的方式合计减持公司股份 不超过1270.8万股，合计减持比例不超过公司股份总数的3%。 ...

Core Viewpoint - The company Huayu Pharmaceutical (688553.SH) announced that its shareholder, Ms. Wang Xiaopeng, plans to reduce her stake in the company by a total of up to 12.708 million shares, which represents a maximum reduction of 3% of the company's total shares [1] Summary by Relevant Categories Shareholder Actions - Ms. Wang Xiaopeng intends to reduce her holdings through centralized bidding and block trading methods [1]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-077 四川汇宇制药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露之日，四川汇宇制药股份有限公司(以下简称"公司")股 东王晓鹏女士持有公司股份数量为 17,037,557 股，占公司总股本的 4.022%； 上述股份来源于公司首次公开发行前取得的股份，且已于 2022 年 10 月 26 日起解除限售并上市流通。 减持计划的主要内容 因自身资金需求，股东王晓鹏女士拟通过集中竞价和大宗交易的方式合计 减持公司股份不超过 12,708,000 股，合计减持比例不超过公司股份总数的 3%。减持期间为自本公告披露之日起 15 个交易日后的 3 个月内。 若减持计划实施期间公司有派息、送股、资本公积金转增股本、配股等除 权除息事项，减持股份数将进行相应调整。 | 股东名称 | 王晓鹏 | | | --- | --- | --- | | 股东身份 | 控股股东、实控人及一 ...

人民财讯9月24日电，汇宇制药(688553)9月24日公告，公司持股4.02%的股东王晓鹏拟通过集中竞价减 持不超过423.6万股、大宗交易减持不超过847.2万股，合计减持不超过1270.8万股，减持比例不超过 3%。 ...

南财智讯9月24日电，汇宇制药公告，王晓鹏女士计划通过集中竞价和大宗交易的方式合计减持不超过 1270.8万股，即不超过公司总股本的3%。减持期间为2025年10月24日至2026年1月21日。若减持计划实 施期间公司有派息、送股、资本公积金转增股本、配股等除权除息事项，减持股份数将进行相应调整。 本次减持计划将严格遵守相关法律法规，切实履行相关承诺，并及时履行信息披露义务。 ...

汇宇制药公告，股东王晓鹏女士持有股份1703.76万股，占公司总股本4.022%；因自身资金需求，拟自 2025年10月24日至2026年1月21日，通过集中竞价减持不超过423.6万股、大宗交易减持不超过847.2万 股，合计减持不超过1270.8万股，减持比例不超过3%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688553 证券简称：汇宇制药 公告编号：2025-076 四川汇宇制药股份有限公司 持股5%以上股东部分股份被轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 四川汇宇制药股份有限公司（以下简称"公司"）股东黄乾益直接持有公司股份27,219,439股，占公司 总股本比例为6.426%。 ● 2025年9月19日，股东黄乾益先生持有公司股份被四川天府新区人民法院司法轮候冻结280,000股。截 至本公告披露日，股东黄乾益先生持有公司股份中21,711,132股被司法冻结，前述股份均处于司法冻结/ 司法标记状态。本次披露的轮候冻结事项不会对公司日常经营与管理造成影响。 ■ 二、股东股份累计被冻结情况 截至公告披露日，上述股东累计被冻结股份情况如下： ■ 三、本次解除冻结/冻结对公司的影响及风险提示 黄乾益先生不属于公司的控股股东或第一大股东及其一致行动人，上述事项不会对公司控制权发生影 响，亦不会对公司生产经营产生重大影响。公司 ...

Core Viewpoint - The announcement from Huili Pharmaceutical indicates that a significant portion of shares held by the second-largest shareholder, Huang Qianyi, has been judicially frozen due to a debt contract dispute, but this will not impact the company's control or operations significantly [1][2]. Group 1: Shareholder Information - Huang Qianyi holds 27,219,439 shares, representing 6.426% of the total share capital of Huili Pharmaceutical [2]. - A total of 21,711,132 shares held by Huang have been frozen, accounting for 79.763% of his holdings and 5.125% of the company's total shares [2]. - The freezing of shares is related to a private lending dispute with Jin Zuping, who has sought property preservation through the court [2]. Group 2: Company Performance - For the first half of 2025, Huili Pharmaceutical reported revenue of approximately 453 million yuan, a decrease of 14.86% year-on-year [3]. - The net profit attributable to shareholders was approximately -80.72 million yuan, representing a decline of 223.78% year-on-year, marking the first loss in interim performance since the company went public [3]. - The basic earnings per share were reported as a loss of 0.19 yuan [3]. Group 3: Market Performance - As of September 22, the stock price of Huili Pharmaceutical closed at 24.82 yuan per share, reflecting a 1.06% increase on that day, with a total market capitalization of 10.51 billion yuan [4]. - Since the beginning of 2025, the stock price has increased by 68.39% [4].

证券代码：688553 证券简称：汇宇制药 公告编号：2025-076 四川汇宇制药股份有限公司 持股 5%以上股东部分股份被轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 四川汇宇制药股份有限公司（以下简称"公司"）股东黄乾益直接持有公 司股份 27,219,439 股，占公司总股本比例为 6.426%。 2025 年 9 月 19 日，股东黄乾益先生持有公司股份被四川天府新区人民 法院司法轮候冻结 280,000 股。截至本公告披露日，股东黄乾益先生持 有公司股份中 21,711,132 股被司法冻结，前述股份均处于司法冻结/司法 标记状态。本次披露的轮候冻结事项不会对公司日常经营与管理造成影 响。 | | | 二、股东股份累计被冻结情况 截至公告披露日，上述股东累计被冻结股份情况如下： | 股东名称 | 持 数 | 股 | 量 | 持股比例 | 累计被司法冻结数 | 占其所持股 | 占公司总股 | | --- | --- | --- | --- | --- | --- | --- | ...